Search
for
Sort by
Research 961–990 of 1000+
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- <i>In Vivo</i>Evaluation of<i>Galla chinensis</i>Solution in the Topical Treatment of Dermatophytosis
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study
- Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review
- Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
- Serum interleukin-37 and its gene polymorphism (rs3811047) in Egyptian patients with alopecia areata
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- The Relationship Between ABO And Rh Blood Groups With Alopecia Areata
- Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
- Not just thinning: A case of alopecia universalis after mild COVID-19
- Black dots in trichoscopy after COVID‐19. Can it be telogen effluvium?
- Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy
- Cellular retinol‐binding protein‐1 expression increases with increasing clinical severity of alopecia areata
- A clinical study on alopecia areata
- Etiopathogenesis of Alopecia Areata
- Finasteride: Middle-Age Cure-All for Alopecia and Benign Prostatic Hyperplasia?–Reply–I
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
- Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Dermoscopic Analysis of Patients with and without Poor Prognostic Indicators in Alopecia Areata – A Comparative Study
- Complete responses and SALT zero scores in alopecia areata: not the same
- 723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study
- A new era for alopecia areata: New treatments and improved knowledge of the condition
- Systemic Tofacitinib in Alopecia Areata: A Single Center Retrospective Descriptive Cohort Study
- Excimer Light versus Combination of Tacrolimus and Excimer Light in the Treatment of Alopecia Areata
- A comparative study of fractional CO2 laser with topical triamcinolone acetonide versus intralesional triamcinolone acetonide in the treatment of alopecia areata
- Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2